Bio-Techne Corporation Stock Price and Value Analysis

Bio-Techne Corporation (NasdaqGS:TECH) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Bio-Techne Corporation to reach your target.

Target type

TECH Free Cash Flow Trend

Free Cash Flow trendline for TECH
Free Cash Flow trendline for Bio-Techne Corporation
CSV

Based on historical returns, we believe that Bio-Techne Corporation can grow its free cash at a rate of about 11%. That's positive!

AdvantagesDisadvantages
  • This company has stable growth.
  • This company is making money at a great rate!
  • This stock looks overpriced.
  • This company has a low dividend yield.
  • This company is less known than others.

Inside the TECH Numbers

TECH Price
(Bio-Techne Corporation stock price per share)
$72.70
[?] TECH Fair Price
(based on intrinsic value)
$38.15
[?] TECH Safety Price (based on a variable margin of safety) $22.89
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 229% higher than other Healthcare stocks
[?] PE Ratio versus Industry 15% higher than other Biotechnology stocks
[?] Cash Yield 1.37%
[?] Free Cash Flow Jitter 21%
[?] Dividend Yield 0.33% (tax impact)
Shares Shorted 7,703,626

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 7,703,626 shares shorted. With 156,380,677 shares available for purchase and an average trading volume over the past 10 trading days of 3,326,440, it would take at least 2.3 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2009 842023 105
2010 842023 106
2011 842023 122
2012 842023 122
2013 842023 115
2014 842023 127
2015 842023 126
2016 842023 128
2017 842023 126
2018 842023 153
2019 842023 162
2020 842023 179
2021 842023 321
2022 842023 288
2023 842023 213
2024 842023 251
2025 842023 243
2026 842023 251

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 17 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled $3,240 million against net income of $2,342 million, or 1.38 times.

In 2025, operating cash flow was 3.92 times net income, compared with 1.07 times for the earliest three years (2009 to 2011).

In 2025, capital expenditures were $31 million, 10.8% of operating cash flow of $288 million, which leaves an estimated $257 million after capex. Across the 17 years with reported capex, it averaged 13.2% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2009 105 111 6.6 1.06
2010 110 111 4.6 1.01
2011 112 127 3.6 1.13
2012 112 127 6 1.13
2013 113 124 22.5 1.10
2014 111 137 13.8 1.23
2015 108 139 19.9 1.29
2016 104 144 16.9 1.38
2017 76.1 144 15.2 1.89
2018 126 170 20.9 1.35
2019 96.1 182 25.4 1.89
2020 229 205 51.7 0.89
2021 140 352 44.3 2.51
2022 272 325 44.9 1.20
2023 285 254 38.2 0.89
2024 168 299 62.9 1.78
2025 73.4 288 31 3.92

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2017 to 2026 with dividend or share repurchase facts, estimated free cash flow totaled $2,187 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $493 million, 22.6% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 10 of those 10 years.

In 8 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $687 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2026, dividends and cash spent repurchasing shares together were $91.6 million, 36.5% of estimated free cash flow of $251 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2017 126 47.3 n/a 47.3 37.5%
2018 153 48 n/a 48 31.4%
2019 162 48.4 15.4 63.8 39.4%
2020 179 48.9 50.1 99 55.3%
2021 321 49.6 43.2 92.8 28.9%
2022 288 50.2 161 211 73.4%
2023 213 50.3 19.6 69.8 32.7%
2024 251 50.4 80 130 52.1%
2025 243 50.4 276 326 134.0%
2026 251 49.9 41.7 91.6 36.5%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $264 million in 2009 and $1,215 million in 2026, a compound annual growth rate of 9.4% over 17 years.

Revenue fell 0.4% from 2025 to 2026.

Our estimated free cash flow was $251 million in 2026, 20.6% of revenue. In 2009 the estimated margin was 39.7%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 264 105 39.7%
2010 269 106 39.3%
2011 290 122 42.2%
2012 315 122 38.6%
2013 311 115 37.0%
2014 358 127 35.4%
2015 452 126 27.9%
2016 499 128 25.7%
2017 563 126 22.4%
2018 643 153 23.8%
2019 714 162 22.7%
2020 739 179 24.3%
2021 931 321 34.4%
2022 1,106 288 26.0%
2023 1,137 213 18.8%
2024 1,159 251 21.6%
2025 1,220 243 19.9%
2026 1,215 251 20.6%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2026, cash and equivalents were $265 million against total liabilities of $479 million, or 55.3% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 18.5% of total assets in 2026, compared with 3.3% in 2010, an increase of 15.2 percentage points.

Stockholders equity was $2,108 million in 2026, compared with $456 million in 2009, a rise of 361.8%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 11.6% in 2026. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2009 472 161 n/a 456
2010 519 94.1 17 502
2011 618 77.6 31.5 586
2012 719 117 44.9 674
2013 778 164 40.6 738
2014 862 319 67.2 795
2015 1,063 54.5 216 847
2016 1,130 64.2 250 879
2017 1,558 91.6 609 950
2018 1,593 122 514 1,079
2019 1,884 101 719 1,166
2020 2,028 147 646 1,381
2021 2,263 199 692 1,571
2022 2,295 173 594 1,701
2023 2,639 181 672 1,967
2024 2,704 152 635 2,069
2025 2,558 162 639 1,919
2026 2,587 265 479 2,108

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $72.70, our model's value equals that price if free cash flow grows an average of 22.7 percent a year over the 10 projection years. Our model assumes 10.7 percent a year for this stock, so the price implies growth of 22.7 percent, which is above the 10.7 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

At 22.7 percent a year, free cash flow would grow about 7.7 times over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $156 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $58.16 18.8%
Current price $72.70 22.7%
20 percent above the current price $87.24 25.8%
Our model (stored fair price) $38.15 10.7%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Every one of the 18 fiscal years we have for Bio-Techne Corporation under its current filer shows positive free cash flow.

Free cash flow from the first three years of data averaged $111 million, and from the last three $248 million: a sharp rise.

Year-to-year variability in free cash flow is fairly steady, measured at 21%.

At $72.70, Bio-Techne Corporation trades above our fair value estimate of $38.15.

Bio-Techne Corporation yields 0.33% in dividends.

Before you act on any of this, read what a margin of safety means and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 229% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 15% above the average for stocks in the Biotechnology industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Biotechnology industry, the ones closest in market capitalization to Bio-Techne Corporation, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Bio-Techne Corporation (TECH) 11,420 66.7 0.3% 1.4% 91% above
Repligen Corporation (RGEN) 10,886 - - - 417% above
Neurocrine Biosciences (NBIX) 15,850 23.2 - - 491% above
Biogen (BIIB) 36,531 107.0 - 9.9% 69% below
Amgen (AMGN) 237,363 25.4 2.2% 4.4% 11% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 842023.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2026
Price and market data last refreshed
2026-11-19
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: TECH annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in TECH

Does Bio-Techne Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: TECH

This example shows how we apply the Trendshare checklist to TECH: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 72.70
    • Market cap: $11B
    • EPS: 1.09
  2. Step 2 — Valuation checks

    • P/E: 66.697
    • FCF yield: 1.4%
    • Date checked: Nov 19, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.